Liraglutide Cost in New Hampshire 2026: Prices, Insurance, Medicaid, and Compounding

What Does Liraglutide Cost in New Hampshire in 2026?

Retail liraglutide prices in New Hampshire span a wide range in 2026, from roughly $150 per month for compounded versions to $1,349 per month at the Novo Nordisk manufacturer list price. The average cash-pay price across New Hampshire retail pharmacies sits at approximately $900 per month, which is what most uninsured or underinsured patients pay out of pocket when filling a brand-name prescription without a savings card or coupon.

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in 2010 for type 2 diabetes management under the brand name Victoza and in 2014 for chronic weight management under the brand name Saxenda [1]. The drug works by mimicking endogenous GLP-1, increasing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [2]. Because Novo Nordisk holds market exclusivity in the United States for both indications through at least mid-decade, true generic liraglutide tablets or injections are not yet commercially available at retail pharmacies in New Hampshire as of 2026.

The SCALE Obesity and Prediabetes trial (N=3,731) published in the New England Journal of Medicine in 2015 reported a mean weight loss of 8.4 kg with liraglutide 3.0 mg versus 2.8 kg with placebo at 56 weeks, with 63.2% of liraglutide patients achieving at least 5% body weight reduction [3]. Those results established liraglutide as a clinically meaningful weight-loss agent, which is part of why demand, and pricing pressure, remains high.

For New Hampshire residents, the practical cost question comes down to four access pathways: brand-name retail with insurance, brand-name retail with a savings card, compounded liraglutide through a 503A pharmacy, or participation in a clinical program. Each pathway carries a different price point and a different set of requirements.

New Hampshire Medicaid Coverage for Liraglutide

New Hampshire Medicaid does not cover liraglutide for chronic weight management or type 2 diabetes as of 2026. Patients enrolled in NH Medicaid (administered through the NH Department of Health and Human Services under the Granite Advantage Health Care Program) cannot use their Medicaid card to fill a Saxenda or Victoza prescription at a New Hampshire pharmacy without prior authorization that is, in practice, rarely granted for this drug class.

This gap is significant given national obesity prevalence data. The CDC reports that New Hampshire's adult obesity rate reached 34.5% in 2023, placing the state in a bracket where GLP-1 access is a genuine public health issue [4]. The American Diabetes Association's 2024 Standards of Care state that "for patients with type 2 diabetes and overweight or obesity, GLP-1 receptor agonists should be considered as a first-line pharmacologic option," yet NH Medicaid's formulary does not reflect that guidance [5].

Patients covered by NH Medicaid who need a GLP-1 agent for type 2 diabetes may have access to older, less expensive agents such as exenatide (Byetta) or oral semaglutide (Rybelsus) through the Medicaid preferred drug list, but liraglutide specifically remains off-formulary. A formal prior authorization appeal citing medical necessity, documented failure of metformin, and HbA1c above 8% may succeed in individual cases, though no systematic data on NH Medicaid GLP-1 approval rates is publicly available.

The Endocrine Society's Clinical Practice Guideline on pharmacological management of obesity (2015, updated 2022) recommends that payers cover anti-obesity medications when BMI meets threshold criteria, noting that failure to cover these drugs increases long-term costs from cardiovascular and metabolic disease [6]. NH Medicaid has not yet adopted that framework.

Compounded Liraglutide in New Hampshire: Legality and Cost

Compounded liraglutide is legal in New Hampshire when prepared by a licensed 503A pharmacy operating under state board of pharmacy oversight. The average price for compounded liraglutide through a New Hampshire or out-of-state 503A pharmacy shipping to NH residents is approximately $150 per month, roughly one-sixth the retail cash-pay price for the brand-name product.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed pharmacists may compound drug preparations for individual patients upon receipt of a valid prescription [7]. Liraglutide's active pharmaceutical ingredient (API) is available from FDA-registered bulk suppliers, and its preparation does not currently appear on FDA's list of drugs that may not be compounded under Section 503A [8]. This means a New Hampshire-licensed 503A pharmacy, or an out-of-state 503A pharmacy licensed to ship into NH, can legally prepare liraglutide injections for individual patients.

Patients should confirm three things before ordering compounded liraglutide: that the pharmacy holds a valid New Hampshire board of pharmacy license (or a reciprocal license permitting interstate shipping), that the pharmacy can provide a certificate of analysis from an accredited third-party lab showing potency and sterility, and that their prescriber is issuing a patient-specific prescription rather than a standing order for non-patient-specific bulk dispensing, which would require 503B outsourcing facility status [9].

The FDA issued a guidance document in 2023 clarifying that compounded semaglutide and liraglutide preparations are not the same as FDA-approved products and that patients assume additional risk when choosing compounded versions [10]. 503A compounding of liraglutide has operated under state pharmacy board oversight for years, and no widespread safety incident specific to liraglutide compounding has been reported in the peer-reviewed literature as of 2025.

A practical quality checklist for evaluating a 503A liraglutide pharmacy in New Hampshire:

1. Valid NH Board of Pharmacy license or active reciprocal shipping license
2. Third-party certificate of analysis (COA) for every batch, showing API potency within 90-110% of label claim
3. Sterility and endotoxin testing per USP 797 standards [11]
4. Refrigerated shipping with temperature logs
5. Prescriber relationship confirmed before dispensing (no dispensing from standing orders)

Brand-Name Liraglutide Prices at New Hampshire Pharmacies

Brand-name Saxenda (liraglutide 3 mg/0.5 mL prefilled pen, 5-pen carton) carries a Novo Nordisk list price of $1,349 per month in 2026. Brand-name Victoza (liraglutide 1.2 mg or 1.8 mg) for diabetes carries a similar list price. The average contracted price that New Hampshire retail pharmacies charge cash-pay customers is approximately $900 per month after standard pharmacy discounts are applied.

GoodRx and similar coupon platforms list Saxenda prices at selected New Hampshire pharmacies ranging from approximately $820 to $1,100 per month depending on zip code and pharmacy chain. CVS locations in Manchester and Nashua, for example, show GoodRx prices near $870 for a 5-pen carton. Independent pharmacies in less competitive rural NH markets (Conway, Littleton, Colebrook) may charge closer to list price without coupon assistance.

The Victoza copay card from Novo Nordisk can reduce out-of-pocket costs to as low as $25 per month for commercially insured patients who meet eligibility criteria, though it explicitly excludes patients covered by any government insurance program, including Medicaid, Medicare Part D, and CHIP [12]. The Saxenda savings card operates under the same eligibility restrictions. Neither card benefits the NH Medicaid population.

A 2023 JAMA Internal Medicine analysis of GLP-1 drug prices found that list prices for liraglutide and semaglutide products in the United States were three to five times higher than in comparable high-income countries, attributing the gap to patent protections and formulary negotiation structures [13]. That pricing environment directly affects what New Hampshire patients pay at the pharmacy counter.

Insurance Coverage for Liraglutide in New Hampshire

Private insurance coverage for liraglutide in New Hampshire varies by employer plan, insurance carrier, and indication. Coverage for Victoza (diabetes indication) is substantially more common than coverage for Saxenda (weight management indication), because most commercial plans tier GLP-1 agents for diabetes more favorably than anti-obesity medications.

Major carriers with significant New Hampshire enrollment, including Anthem Blue Cross Blue Shield NH, Harvard Pilgrim Health Care, and Tufts Health Plan, generally place Victoza on Tier 3 of their standard formularies, resulting in copays of $50 to $150 per month after deductible for commercially insured patients. Saxenda's placement varies: some Anthem NH plans cover it on Tier 3 or 4 with prior authorization requiring documented BMI of 30 or higher (or 27 with a weight-related comorbidity), while others exclude it entirely as a "lifestyle" medication [14].

The Affordable Care Act does not mandate coverage of anti-obesity medications. The USPSTF gave intensive behavioral weight-loss interventions a Grade B recommendation in 2018, which requires ACA-compliant plans to cover behavioral counseling, but pharmacologic weight management does not carry the same mandate [15]. That gap is one reason why coverage for Saxenda specifically remains inconsistent across NH plans.

Employer self-funded plans (common among New Hampshire's large manufacturing and tech employers, such as those along the Route 3 corridor) set their own formularies and may exclude anti-obesity drugs entirely. Employees on those plans should review the Summary Plan Description or contact HR directly rather than assuming that the carrier's retail formulary applies.

Medicare Part D covers Victoza for type 2 diabetes when the patient's plan includes it on formulary; typical Part D copays for Victoza range from $50 to $200 per month in the coverage phase. Medicare Part D does not cover Saxenda for weight management, a restriction that remains in effect unless the Treat and Reduce Obesity Act (introduced in the 118th Congress but not yet enacted) passes into law [16].

Telehealth Prescribing of Liraglutide in New Hampshire

Liraglutide can be prescribed via telehealth in New Hampshire under state law. New Hampshire does not require an in-person visit before a prescriber can issue a controlled or non-controlled prescription through a synchronous audio-video telehealth encounter, as long as the prescriber holds a valid New Hampshire license or a license in a compact member state through which they are practicing [17].

Liraglutide is not a DEA scheduled substance, which means the DEA's temporary COVID-era telemedicine prescribing rules (and their eventual permanent successors) do not apply. Prescribers can issue liraglutide prescriptions after a telehealth visit without additional restrictions beyond standard standard-of-care obligations: a clinical assessment, documentation of indication, and appropriate follow-up planning.

A typical telehealth workflow for liraglutide in New Hampshire involves an initial video consultation (approximately 20 to 40 minutes), baseline labs (HbA1c, fasting glucose, lipids, and a thyroid screen given liraglutide's FDA black-box warning for thyroid C-cell tumors in rodents), and a prescription sent electronically to a New Hampshire pharmacy or compounding pharmacy of the patient's choice. Follow-up visits are typically scheduled at 4 to 8 weeks to assess tolerability and dose titration.

The SCALE Obesity trial used a titration schedule starting at 0.6 mg once daily for one week, increasing by 0.6 mg each week to the maintenance dose of 3.0 mg daily [3]. Telehealth prescribers following that protocol typically communicate titration schedules via secure messaging through the patient portal between visits, a workflow that New Hampshire telehealth law explicitly permits [17].

How to Get the Lowest Liraglutide Price in New Hampshire

The lowest reliably accessible price for liraglutide in New Hampshire in 2026 is approximately $150 per month through a licensed 503A compounding pharmacy. For patients who prefer or require FDA-approved brand-name liraglutide, the practical floor with commercial insurance and a Novo Nordisk savings card is approximately $25 per month, though that requires active commercial insurance, not Medicaid or Medicare.

For uninsured or NH Medicaid patients seeking brand-name liraglutide, Novo Nordisk's Patient Assistance Program (NovoCare) provides Saxenda and Victoza at no cost to patients with household incomes at or below 400% of the federal poverty level who are uninsured or underinsured [18]. The application requires income documentation and a prescriber signature. Processing typically takes 3 to 6 weeks, and medication is shipped directly to the prescriber's office or the patient's home.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not yet carry liraglutide as of early 2025, as the product lacks a generic equivalent. If a generic liraglutide receives FDA approval and Cost Plus adds it to their catalog, New Hampshire patients could potentially access it at a fraction of current retail prices, potentially in the $100 to $200 per month range based on the cost-plus markup model applied to other injectables on that platform.

The NEJM 2022 analysis of semaglutide and liraglutide cost-effectiveness found that liraglutide at list price was not cost-effective relative to placebo at standard willingness-to-pay thresholds of $100,000 per quality-adjusted life-year, but that a price reduction to approximately $200 per month would bring it within cost-effective range [19]. That analysis underscores why access to compounded or discounted liraglutide matters clinically, not only financially.

Dose Titration, Administration, and Clinical Monitoring in New Hampshire

Liraglutide for weight management is administered as a once-daily subcutaneous injection, typically in the abdomen, thigh, or upper arm, at any time of day regardless of meals. The standard titration schedule endorsed by the FDA label for Saxenda begins at 0.6 mg daily for one week and increases by 0.6 mg each week until the 3.0 mg maintenance dose is reached [1]. Patients who cannot tolerate titration to 3.0 mg should not continue on lower maintenance doses, per label guidance, because weight-loss efficacy is substantially reduced below the full maintenance dose.

For type 2 diabetes (Victoza), the starting dose is 0.6 mg daily for one week, followed by 1.2 mg daily; the dose may be increased to 1.8 mg if additional glycemic control is needed [20]. The diabetes indication does not require titration to 3.0 mg and in practice most patients are maintained at 1.2 or 1.8 mg.

Contraindications include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), consistent with the FDA black-box warning [1]. Patients with a history of pancreatitis are typically excluded from liraglutide therapy based on prescribing label language, although causation between GLP-1 agonists and pancreatitis in humans has not been definitively established in the literature [21].

Monitoring recommended at baseline and follow-up includes: HbA1c (diabetes patients), fasting glucose, renal function (eGFR), and heart rate. Liraglutide produced a modest increase in mean resting heart rate of approximately 2 to 3 beats per minute in the SCALE trial, which warrants monitoring in patients with pre-existing tachycardia [3]. The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced the risk of major adverse cardiovascular events (MACE) by 13% relative to placebo in patients with type 2 diabetes and established cardiovascular disease (HR 0.87 to 95% CI 0.78-0.97, P<0.001 for non-inferiority; P=0.01 for superiority) [22].

New Hampshire prescribers should be aware that the NH Board of Medicine and the NH Board of Pharmacy both apply standard-of-care expectations from the Endocrine Society and ADA guidelines to liraglutide prescribing, including the requirement for documented therapeutic monitoring regardless of whether the prescription is issued in-person or via telehealth [6].

New Hampshire Discount Programs and Patient Assistance for Liraglutide

Beyond the Novo Nordisk NovoCare patient assistance program described above, New Hampshire residents have access to several additional cost-reduction pathways for liraglutide.

The NH 340B Drug Pricing Program allows federally qualified health centers (FQHCs) and other covered entities in New Hampshire to purchase outpatient drugs at significant discounts and pass those savings to eligible low-income patients [23]. New Hampshire FQHCs include Greater Nashua Mental Health (which operates primary care), Concord-based Capital Region Family Health Center, and several community health centers in the North Country. Patients who receive care at these sites may access Victoza or Saxenda at sharply reduced cost if the site participates in 340B and stocks these agents.

State pharmaceutical assistance programs in New Hampshire are limited. The NH Senior Prescription Drug Discount Program (SeniorCare) provides modest discounts on prescription drugs for residents aged 65 and older who do not qualify for Medicare Part D Low Income Subsidy, though GLP-1 agents are not priority drugs under that program [24].

GoodRx Gold membership ($9.99/month) consistently shows discounts at NH pharmacies on Victoza ranging from 15% to 25% below standard GoodRx prices, which may bring costs below $800 per month at selected locations. Blink Health and RxSaver show similar NH-specific pricing, with variation by zip code.

Why Generic Liraglutide Is Not Yet Available in New Hampshire

No FDA-approved generic liraglutide (in the sense of an ANDA-approved small-molecule or biosimilar injectable) is commercially available in New Hampshire or any other U.S. State as of early 2026. Liraglutide is a 31-amino-acid acylated analog of human GLP-1, making it a peptide rather than a small molecule [2]. That classification means generic entry follows the 351(k) biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA), not the standard Paragraph IV ANDA pathway [25].

To receive FDA interchangeable biosimilar designation, a liraglutide biosimilar manufacturer would need to complete reference product exclusivity periods, conduct comparative clinical studies demonstrating no clinically meaningful differences from the reference product, and pass FDA inspection of the manufacturing facility [25]. No liraglutide biosimilar application had received FDA approval as of the publication date of this article.

This is why "compounded liraglutide" is the closest available lower-cost analog for New Hampshire patients. Compounded preparations use synthesized liraglutide API, which is distinct from an FDA-approved biosimilar and carries different regulatory and quality-control implications. The distinction matters: FDA-approved biosimilars undergo extensive clinical comparison studies, while compounded API preparations rely on third-party COA testing and USP 797 sterility standards, which are rigorous but not equivalent to the full FDA approval process [10].

Once a biosimilar liraglutide receives FDA approval and launches commercially, New Hampshire pharmacies should be able to stock it, and Part D plans and NH commercial insurers would be expected to cover it with biosimilar tier pricing. Analyst estimates place potential biosimilar liraglutide pricing at $300 to $500 per month at commercial launch in the United States, though no publicly confirmed timeline exists for that launch as of early 2025.